VSV-GP128
- Generic Name
- VSV-GP128
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Phase 1
Active, not recruiting
- Conditions
- Stage IV Colon CancerLiver Metastasis Colon CancerColorectal CancerMSSStage IV Rectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Amal Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT04046445
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇨ðŸ‡University Hospital Zurich, Zürich, Zurich, Switzerland
🇧🇪University Hospital Antwerpen, Edegem, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath